Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus

Clinica Chimica Acta

Volumn 412, Issue 3-4, 2011, Pages 322-326

  Chang, Horng Rong ^a,b   Yang, Shun Fa ^b   Tsai, Jen Pi ^c   Hsieh, Ming Chia ^d   Wu, Sheng Wen ^a   Tsai, Hui Ching ^a   Hung, Tung Wei ^a,b   Huang, Jun Huang ^b   Lian, Jong Da ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Gene polymorphism; Kidney transplantation; Plasminogen activator inhibitor 1; Posttransplant diabetes mellitus

Indexed keywords

CYCLOSPORIN; GENOMIC DNA; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISOLONE; TACROLIMUS;

ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; DNA ISOLATION; EVENT FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HOMOZYGOSITY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OBSERVATIONAL STUDY; POSTTRANSPLANT DIABETES MELLITUS; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTECTION;

ADULT; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 78650232262     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.10.029     Document Type: Article

References (25)

1. Kasiske B.L., Snyder J.J., Gilbertson D., Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185.
2. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003, 3:590-598.
3. Bloom R.D., Crutchlow M.F. Transplant-associated hyperglycemia. Transplant Rev 2008, 22:39-51.
4. van Hooff J.P., Christiaans M.H., van Duijnhoven E.M. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 2005, 79:1465-1469.
5. Juhan-Vague I., Alessi M.C., Morange P.E. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000, 32(Suppl 1):78-84.
6. Herlihy O.M., Barrow B.A., Grant P.J., Levy J.C. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling. Diabetologia 2002, 45:635-641.
7. Aldamiz-Echevarria L., Sanjurjo P., Vallo A., et al. Genetic and metabolic determinants of increased plasma plasminogen activator inhibitor-1 activity in children with renal transplants. Pediatr Nephrol 2003, 18:749-755.
8. Chang H.R., Yang S.F., Lian J.D., et al. Prediction of chronic allograft damage index of renal allografts using serum level of plasminogen activator inhibitor-1. Clin Transplant 2009, 23:206-212.
9. Nordt T.K., Lohrmann J., Bode C. Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis. Thromb Res 2001, 103(Suppl 1):S1-S5.
10. Leipold H., Knoefler M., Gruber C., Klein K., Haslinger P., Worda C. Plasminogen activator inhibitor 1 gene polymorphism and gestational diabetes mellitus. Obstet Gynecol 2006, 107:651-656.
11. Clinical practice recommendations Diab Care 2005, 28(Suppl 1):S1-S79.
12. Saely C.H., Muendlein A., Vonbank A., et al. Type 2 diabetes significantly modulates the cardiovascular risk conferred by the PAI-1-675 4G/5G polymorphism in angiographied coronary patients. Clin Chim Acta 2008, 396:18-22.
13. Chen C.H., Shu K.H., Wen M.C., et al. Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy. Nephrol Dial Transplant 2008, 23:3166-3173.
14. Fabrizi F., Martin P., Dixit V., Bunnapradist S., Kanwal F., Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant 2005, 5:2433-2440.
15. van Hooff J.P., Christiaans M.H., van Duijnhoven E.M. Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 2004, 19(Suppl 6):vi8-vi12.
16. Numakura K., Satoh S., Tsuchiya N., et al. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. Transplant Proc 2005, 37:1865-1867.
17. Numakura K., Satoh S., Tsuchiya N., et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 2005, 80:1419-1424.
18. Chan H.W., Cheung C.Y., Liu Y.L., et al. Prevalence of abnormal glucose metabolism in Chinese renal transplant recipients: a single centre study. Nephrol Dial Transplant 2008, 23:3337-3342.
19. Knoll G.A., Bell R.C. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. Bret Med J 1999, 318:1104-1107.
20. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002, 346:393-403.
21. Chow K.M., Szeto C.C., Szeto C.Y., Poon P., Lai F.M., Li P.K. Plasminogen activator inhibitor-1 polymorphism is associated with progressive renal dysfunction after acute rejection in renal transplant recipients. Transplantation 2002, 74:1791-1794.
22. Reis K., Arinsoy T., Derici U., et al. Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. Clin Transplant 2005, 19:10-14.
23. Azarpira N., Bagheri M., Raisjalali G.A., et al. Angiotensinogen, angiotensine converting enzyme and plasminogen activator inhibitor-1 gene polymorphism in chronic allograft dysfunction. Mol Biol Rep 2009, 36:909-915.
24. Lahlou A., Peraldi M.N., Thervet E., et al. Chronic graft dysfunction in renal transplant patients: potential role of plasminogen activator inhibitor type 1. Transplantation 2002, 73:1290-1295.
25. Rerolle J.P., Munteanu E., Drouet M., et al. PAI-1 donor polymorphism influences long-term kidney graft survival. Nephrol Dial Transplant 2008, 23:3325-3332.